Highly doubt the same because OWC has always wished to remain autonomous and focus on research while outsourcing the IP for the markets. That said I wouldn't complain if it was as it would mean a buy out which likely would mean a conversion to Pfizer shares instead of cash buy out. At which point the conversion ratio would be what mattered to all of us.

Again... I really think this is not in the direction of what OWC envisions for itself as they have outlined multiple times.

That doesn't mean however that OWC wouldn't be a great fit for Pfizer to collaborate with to bring products world wide.